Gerry Evans Email & Phone Number

South Carolina, United States

United Kingdom

NeuSensors Limited is creating a unique drug development platform that outperforms all current molecular binding measurement techniques. This will allow for the combination of multiple analytics in a single operation.The Problem:- Current techniques including SPR, Elisa Assays, NMR, X-Ray etc. require multiple steps and significant expertise to run and interpret in controlled laboratory settings. They usually only measure response against a single analyte and have difficulties measuring certain targets and weak binders. They can also require special licensing and are very expensive.Technology:- The NeuSensors’ technology • provides information on multiple markers / data points including off-target effects in a single step “Direct Read” system requiring no special expertise. • is easily configured to analyze any target and is very effective with weak binders and does not require a controlled laboratory setting.• is produced at low cost and will not require special licensing therefore the cost savings will be significant.

Greenville, South Carolina Area

Biohub @ Alderley, Chesire, United Kingdom

NeuDrive Ltd, founded in 2014, has patents on the world’s highest performance inks and manufacturing processes for printing Organic Thin Film Transistors for high performance, low cost electronics applications in flexible displays, wearable electronics, sensors and point of care diagnostics.Our initial focus is BioSensors for Drug Development

BioLeap is a drug discovery company enabled by the next generation of computational fragment-based design technology. BioLeap’s design platform quickly predicts binding affinity based on thermodynamic principles giving drug designers new insights to efficiently create non-obvious molecules and improve existing molecules. Lack of chemical diversity has blocked the progress of many high-priority targets during the lead identification and lead optimization phase for failure to provide either a suitable chemical starting point or a replacement structural class to a doomed lead series. BioLeap’s technology provides a viable alternative to high-throughput screening and traditional shape-based “docking” approaches. BioLeap has identified lead compounds in four collaborative ventures and is seeking new partners who are interested in exploiting its compelling compound design and engineering platform.

Greenville, South Carolina Area

Broad experience in funding and growing emerging growth companies:CEO Mentoring, Business Strategy, Officer Level Executive Search